Huafu Securities released a research report on April 20 stating that it maintains Ma Yinglong (600993.SH)'s purchase rating, and the target price is 29.7 yuan. The main reasons for the rating include: 1) high net profit base to achieve positive growth, net profit growth rate after deducting non-return to mother; 2) pharmaceutical industry: optimized inventory structure, smooth channel sorting, and sharp decline in core product inventory; 3) service and commerce: an important fulcrum for building Ma Yinglong's entire anal and intestinal industry chain. (Mainichi Keizai Shimbun)
华福证券4月20日发布研报称，维持马应龙（600993.SH）买入评级，目标价格为29.7元。评级理由主要包括：1）归母净利润高基数实现正增长，扣非归母净利润高增速；2）医药工业：优化存量结构，渠道梳理顺畅，核心产品库存大幅下降；3）服务与商业：打造马应龙肛肠全产业链的重要支点。（每日经济新闻）
Huafu Securities released a research report on April 20 stating that it maintains Ma Yinglong (600993.SH)'s purchase rating, and the target price is 29.7 yuan. The main reasons for the rating include: 1) high net profit base to achieve positive growth, ne
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated